Summary
Alder Biopharmaceuticals Inc (Alder) is a biopharmaceutical company which develops, produces and markets monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease and autoimmune and inflammatory diseases. The company uses technologies such as the antibody selection system and novel mab xpress antibody production system. Its pipeline products include clazakizumab and eptinezumab. Alder’s clazakizumab is a novel monoclonal antibody used for the treatment of rheumatoid arthritis and psoriatic arthritis. The company’s eptinezumab is an investigational product candidate for migraine prevention treatment for patients with chronic and frequent episodic migraine. Alder is headquartered in Bothell, Washington, the US.
Alder Biopharmaceuticals Inc (ALDR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Alder Biopharma Raises US$38 Million In Series D Financing 11
Licensing Agreements 13
Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 13
Equity Offering 14
Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 14
Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 16
Alder BioPharma Raises USD230 Million in Public Offering of Shares 18
Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 20
Alder Biopharma Raises USD88.8 Million in IPO 22
Alder Biopharmaceuticals Inc - Key Competitors 24
Alder Biopharmaceuticals Inc - Key Employees 25
Alder Biopharmaceuticals Inc - Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 08, 2017: Alder BioPharmaceuticals Announces Second Quarter 2017 Financial and Operating Results 27
Apr 27, 2017: Alder BioPharmaceuticals Announces First Quarter 2017 Financial and Operating Results 29
Feb 23, 2017: Alder BioPharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results 31
Oct 27, 2016: Alder BioPharmaceuticals Announces Third Quarter 2016 Financial and Operating Results 33
Jul 26, 2016: Alder BioPharmaceuticals Reports Second Quarter 2016 Financial and Operating Results 35
Apr 28, 2016: Alder BioPharmaceuticals Reports First Quarter 2016 Financial and Operating Results 37
Feb 23, 2016: Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial and Operating Results 39
Corporate Communications 41
Apr 04, 2017: Alder BioPharmaceuticals Appoints Wendy L. Yarno to its Board of Directors 41
Jun 29, 2016: Alder BioPharmaceuticals Appoints Timothy M. Whitaker, M.D., Chief Medical Officer 42
Product News 43
09/06/2016: Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer 43
05/25/2016: Alder BioPharmaceuticals Continues to Strengthen and Expand Leadership Team to Support Advancement of ALD403 for Migraine Prevention 44
03/06/2017: Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention 45
02/09/2016: Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization 46
Clinical Trials 47
Jun 07, 2017: Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society 47
Apr 28, 2017: Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting 48
Apr 24, 2017: Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting 49
Nov 28, 2016: Alder BioPharmaceuticals Initiates PROMISE 2 Pivotal Trial of Eptinezumab for the Prevention of Migraine 50
Sep 15, 2016: Alder Presents Positive ALD403 Clinical Data at European Headache and Migraine Trust International Congress 51
Sep 08, 2016: Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention 52
Jul 25, 2016: Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine 53
Jun 09, 2016: Alder Presents Positive Clinical Data for ALD403 at the Annual Meeting of the American Headache Society 55
Jun 02, 2016: Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention 56
Mar 28, 2016: Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine 57
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59
List of Tables
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Alder Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alder Biopharma Raises US$38 Million In Series D Financing 11
Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 13
Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 14
Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 16
Alder BioPharma Raises USD230 Million in Public Offering of Shares 18
Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 20
Alder Biopharma Raises USD88.8 Million in IPO 22
Alder Biopharmaceuticals Inc, Key Competitors 24
Alder Biopharmaceuticals Inc, Key Employees 25
